Advisors
The Advisory Board of the PiR was established to give a unique cross-cultural insight into the life science industry. Its members gain too, with a stimulating and intimate forum in which leading figures from established and emerging biotechnology and pharmaceutical companies can come together and talk confidentially about the challenges they face. The Board members are recognised as experts in their fields and provide a wealth of experience and perspective in the world of pharmaceuticals and recruitment.
The Advisory Board helps to guide the activities of PiR Interims by identifying common issues the life science industry faces. Crucially, it is a partnership in which the value flows both ways so that the forum is of value to PiR as well as the members. Clients and candidates also gain because the Advisory Board gives PiR Interims a diverse, broad and balanced range of skills, spanning the clients we work with across pharma, biotech, CRO, medical devices and diagnostics sectors:
If you are interested in understanding more about the Advisory Board, please contact Carolyn Douthwaite: cd@pir-interims.com
Dr Ken Cunningham
CEO SkyePharma Plc
Ken is Chief Executive Officer and board director at SkyePharma Plc. He is also non-executive director of Xention Ltd. He was previously CEO of Arakis, vice president European affairs for Alza Corporation and vice president clinical development for Sequus Pharmaceuticals. Prior to this he held a variety of clinical development and commercial strategy positions in GlaxoWellcome and Warner-Lambert. Dr Cunningham qualified from St Mary’s Medical School, London University.
Dr David Ebsworth
Chairman of Wilex AG, A&D Pharma,, Atani and Xention
David is currently Chairman of Wilex AG, A&D Pharma Holdings NV, Atano Ltd and Xention Limited. He is a Non-Executive Director of Intercell AG and Renovo PLC as well as a consultant to the pharmaceutical and biotechnology industries.
In June 2002, David joined Oxford GlycoSciences as an Executive Director and assumed the role of Chief Executive Officer in July 2002. In June 2003, David moved on from his position as Chief Executive Officer following the takeover by Celltech. David has over 25 years experience within the Pharmaceuticals industry. Prior to joining OGS, he was head of the worldwide Pharmaceutical Business Group of Bayer AG. Before that, he was President of Bayer Pharmaceutical Division in North America with responsibility for all functions from research through clinical development, regulatory affairs, sales and marketing, finance and strategy. Previously, he held a number of senior management positions within Bayer in Canada, Europe and the US. In 2001, he received the Global Citizen Award from the School of Diplomacy and International Relations at Seton Hall University in New Jersey. David holds a PhD from Surrey University
Dr Ann Hayes PhD
Independent Consultant and NED
Ann Hayes worked for 22 years for GlaxoWellcome, initially in research, with particular expertise in the areas of CNS and pain. Before the GSK merger, she was a Director in Drug Discovery, and was involved in long-term discovery strategy, portfolio management and discovery project management. Ann left GSK in 2001 to become an independent pharmaceutical consultant and co-founded two pharma companies, Ionix Pharmaceuticals and Therasci, which has since been bought by CeNeS. Ann is a non-executive director and consultant for Ionix, a director for Curidium, and a member of the advisory boards for Biowisdom, Sirenade and BrainCells Inc. She has also held NED positions at Therasci and Sirus (which was recently sold to Arakis) and currently consults regularly for CeNes and Shire, as well as doing ad hoc consulting for a number of small companies and VCs.
Mr Ed Hoskin
Senior Director, Human Resources, Gilead Sciences
Ed Hoskin started his career in finance and the City, before moving into executive search where his clients included many of the major banks and stockbroking institutions. He then moved his career into mainstream Human Resource Management, including 9 years at Genzyme Corporation where he was UK Human Resources Director before moving to Powderject in 2001 to work with the plc Board in shaping the HR strategy and delivery. Upon Chiron’s acquisition of Powderject in July 2003, Ed was appointed Vice President responsible for HR in the new combined business, and a member of the Executive Committee of Chiron Vaccines. Following the successful sale of Chiron to Novartis in April 2006, Ed now leads the International HR organisation for Gilead Sciences where he leads HR across Europe, Australasia, Asia and Latin America. Ed is a Fellow of the Chartered Institute of Personnel & Development, and has an MSc in Strategic International Human Resource Management.
Dr Mark Treherne
Chief Executive of Senexis and on the Board of NeuroDiscovery,
Population Genetics, Xention and Faust Pharmaceuticals
Mark obtained his PhD in neuropharmacology from Cambridge University and now has over 20 years experience in the discovery of novel treatments for diseases of the central and peripheral nervous systems, latterly at Pfizer Central Research. Mark was a founder member and CEO of Cambridge Drug Discovery in 1997 prior to merger with BioFocus plc, where he remained on the Board until 2002. Mark was formerly Chairman of the Eastern Region Biotechnology Initiative and is a visiting Senior Lecturer in Neuroscience at the University of Kent. Currently, Mark is Chief Executive of Senexis and on the Board of NeuroDiscovery, Population Genetics, Xention and Faust Pharmaceuticals. So far, Mark has raised over £60 million for various early stage biotechnology companies.
Mr Jeff Grout
Listed in the '100 Best Business Speakers in Britain', Jeff Grout is in considerable demand as a motivational business speaker, conference chairman and interviewer. Formerly UK Managing Director of a leading international recruitment consultancy and Business Manager to Sir Clive Woodward, Jeff is now an independent business consultant specialising in leadership, people management, team building, peak performance, recruitment and retention issues.
He holds a number of corporate advisory and executive coaching appointments and is also a successful business author. His sixth book entitled 'What do Leaders Really do?' is published in August 2007. Jeff also provides 'Effective Presentation Skills' coaching and is currently working with former England rugby captain Martin Johnson and former England cricket captain Nasser Hussain.
Jeff works with a number of the leading speaking agencies and has spoken for a range of clients including Deloitte & Touche, Morgan Stanley, Tesco, Telewest, Sport England, BAA, Ernst & Young, UBS, Football Association, Strutt & Parker, Chartered Institute of Personnel & Development and Saracens RFC.
Presentations include:
- Building High Performance Teams- What Leaders Really Do
- The Characteristics of Success
- Recruiting Excellence
- The Nature of Entrepreneurship
- Successfully Leading Change
- Sporting Lessons for Business
- Creating the Right Work/Life Balance